PACS Group Growth Looks Solid, But Risks Support A Hold
PACS Group posted second-quarter revenue growth of 9.1% and a 24.6% rise in adjusted EBITDA. The stock trades near $43, or about 15.8 times projected 2027 earnings, and the author rates it Hold. Growth plans include 100 locations under development and the Eduro purchase, but DOJ and SEC probes, California concentration, and audit issues pose risks.
PACS Group operates in U.S. nursing homes, buying struggling facilities and seeking to raise occupancy and care standards. In its second quarter, revenue increased 9.1% and adjusted EBITDA climbed 24.6%. The shares trade near $43, or roughly 15.8 times estimated 2027 earnings, leading the author to a Hold rating.
Future growth includes about 100 sites in development and the Eduro purchase. However, margin gains may moderate as occupancy matures. The company also faces DOJ and SEC probes, heavy California exposure, and unresolved audit matters.
PACS Group’s expansion could affect nursing-home residents, families, staff, and investors. If acquisitions and occupancy gains improve facility performance, access and quality may benefit in some markets. Yet DOJ and SEC scrutiny, California concentration, and audit concerns could raise compliance costs, distract management, or weigh on investor confidence. Regulators and local communities may also watch whether rapid growth preserves care standards. The outcome may depend on how effectively the company addresses oversight and operational risks.